Common Contracts
5 similar Royalty Interest Purchase Agreement contracts by Jaguar Health, Inc.
Royalty Interest Purchase AgreementRoyalty Interest Purchase Agreement • August 30th, 2022 • Jaguar Health, Inc. • Pharmaceutical preparations • Utah
This Royalty Interest Purchase Agreement (this “Agreement”), dated as of August 24, 2022, is entered into by and between Jaguar Health, Inc., a Delaware corporation (“Company”), and Streeterville Capital, LLC, a Utah limited liability company, its successors and/or assigns (“Investor”).
Royalty Interest Purchase AgreementRoyalty Interest Purchase Agreement • March 11th, 2021 • Jaguar Health, Inc. • Pharmaceutical preparations • Utah
This Royalty Interest Purchase Agreement (this “Agreement”), dated as of March 8, 2021, is entered into by and between Jaguar Health, Inc., a Delaware corporation (“Company”), and Streeterville Capital, LLC, a Utah limited liability company, its successors and/or assigns (“Investor”).
ROYALTY INTEREST PURCHASE AGREEMENTRoyalty Interest Purchase Agreement • December 29th, 2020 • Jaguar Health, Inc. • Pharmaceutical preparations • Utah
THIS ROYALTY INTEREST PURCHASE AGREEMENT (this “Agreement”), dated as of December 22, 2020, is entered into by and between JAGUAR HEALTH, INC., a Delaware corporation (“Company”), and IRVING PARK CAPITAL, LLC, a Utah limited liability company, its successors and/or assigns (“Investor”).
ROYALTY INTEREST PURCHASE AGREEMENTRoyalty Interest Purchase Agreement • October 9th, 2020 • Jaguar Health, Inc. • Pharmaceutical preparations • Utah
THIS ROYALTY INTEREST PURCHASE AGREEMENT (this “Agreement”), dated as of October 8, 2020, is entered into by and between JAGUAR HEALTH, INC., a Delaware corporation (“Company”), and ILIAD RESEARCH AND TRADING, L.P., a Utah limited partnership, its successors and/or assigns (“Investor”).
Royalty Interest Purchase AgreementRoyalty Interest Purchase Agreement • March 6th, 2020 • Jaguar Health, Inc. • Pharmaceutical preparations • Utah
This Royalty Interest Purchase Agreement (this “Agreement”), dated as of March 4, 2020, is entered into by and between Jaguar Health, Inc., a Delaware corporation (“Company”), and Iliad Research and Trading, L.P., a Utah limited partnership, its successors and/or assigns (“Investor”).
